T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Shahryar Kiaii, Håkan Mellstedt(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Parviz Kokhaei(Arak University of Medical Sciences), Kaveh Mashayekhi(Karolinska University Hospital), Marzia Palma(Karolinska University Hospital), Lotta Hansson(Karolinska Institutet), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Eva Rossmann(Karolinska University Hospital), Fariba Mozaffari(Karolinska University Hospital), Fatemeh Pak(Karolinska Institutet), Aniruddha Choudhury(Greenslopes Private Hospital), Ali Moshfegh(Karolinska University Hospital)
Cited by 23
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312